Leading the TCR T-Cell Therapy Space

Transforming cancer immunotherapy with affinity enhanced T-cell receptors.

Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for multiple proprietary SPEAR T-cells in solid tumor indications. The Company also has a T-cell program partnered with GSK, which has already shown preliminary evidence of tumor reduction in patients with synovial sarcoma and multiple myeloma.

Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells.

Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality.

Company History

  • 1993-1999

    TCR technology developed at Oxford University

  • 1999

    Avidex was formed on the basis of T cell receptor technology from Oxford University

  • 2006

    Avidex was acquired by Medigene

  • 2008

    Adaptimmune spun out as a virtual company with University of Penn collaboration

  • 2011-2014

    Adaptimmune establishes R&D infrastructure and delivers promising clinical data

  • 2014

    Strategic collaboration with GSK + $104m Series A Funding Round

  • 2015

    Adaptimmune IPO on NASDAQ raises $176 million.

  • 2016

    Breakthrough therapy designation and PRIME regulatory access for NY-ESO SPEAR T-cell therapy

  • 2017

    Option exercise by GSK for exclusive license to NY-ESO SPEAR T-cell program
    Completion of public offering with net proceeds of $61,397,000